EFFICACY OF HEPATITIS B VACCINE IN PREVENTION OF EARLY HBsAg CARRIER STATE IN CHILDREN. Controlled Trial in an Endemic Area (Senegal)

The Lancet

Volumn 317, Issue 8215, 1981, Pages 289-292

  Maupas, P ^a   Barin, F ^a   Chiron, J P ^a   Coursaget, P ^a   Goudeau, A ^a   Perrin, J ^b   Denis, F ^b   Diop Mar, I ^b  

^a Institut de Virologie de Tours Facultés de Médecine et de Pharmacie Tours France ^*

^b CHNU Fann   (Senegal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; HEPATITIS B VACCINE; INACTIVATED VIRUS VACCINE;

CARRIER; GEOGRAPHIC DISTRIBUTION; HEPATITIS B VIRUS; HUMAN CELL; INFANT; LIVER; PRESCHOOL CHILD; VACCINATION;

AGE FACTORS; CARRIER STATE; CHILD, PRESCHOOL; CLINICAL TRIALS; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; MALE; SENEGAL; VACCINATION; VIRAL VACCINES;

EID: 0019366746     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(81)91908-5     Document Type: Article

References (17)

1. A serum antigen (Australia antigen) in Down's syndrome, leukemia and hepatitis
2. 2 strains
3. Prevention of virus B hepatitis (SH hepatitis)
4. Hepatitis B subunit vaccine: a preliminary report of safety and efficacy tests in chimpanzees
5. Purified and inactivated human hepatitis B vaccine: progress report
6. Attempt to prevent hepatitis by using specific anti-HBs immunoglobulin
7. Hepatitis B immune serum globulin and standard gammaglobulin in prevention of hepatitis B infection among hospital staff: a preliminary report
8. Hepatitis B vaccine. Safety criteria and non-B infection
9. Immunisation against hepatitis B in man
10. Clinical and laboratory studies ofHBs Ag vaccine
11. Safety of hepatitis B vaccines: no evidence of autoimmunity
12. Vaccine against hepatitis B-18 months prevention in a high risk setting
13. Hepatitis B vaccine: efficacy in high risk settings, a two year study
14. Efficacy of a vaccine against hepatitis B: epidemiological data
15. Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States
16. Cross-sectional and longitudinal epidemiology of hepatitis B in Senegal
17. Large scale purification of hepatitis B surface antigen (HBsAg)